In June 2020, world-leading Serbian tennis player Novak Djokovic and his wife, Jelena Djokovic, bought an 80% stake in a Danish biotech company whose main feature is the development of an anti-coronavirus treatment. This was reported by Reuters news agency on Wednesday afternoon.
According to a news agency, it is a medical research and development center called QuantBioRes. Ivan Lonkarevich confirmed to the company that the clients are from the Djokovic family, but did not reveal how much they paid for the stake.
QuantBioRes develops peptides that prevent the virus from entering the human cell. Their clinical trials could start as early as the summer in the UK. Lunkarvich confirmed during the investigation that they are not working on a vaccine, but on a treatment.
The company employs about a dozen researchers in Denmark, Australia and Slovenia. A spokesman for Djokovic did not respond to the investigation.
Djokovic, who has not been vaccinated against the coronavirus, has been at the center of the vaccination debate since arriving in Australia on January 5 to defend his Australian Open title. Australia only accepts vaccinated guests, with strict entry rules in place, so at the end of the 11-day jingle Djokovic was eventually deported from the country after his visa was revoked.
The Serbian world leader has a record 20 Grand Slam victories, as well as Rafael Nadal of Spain and Roger Federer of Switzerland, who is currently injured.
Djokovic’s career was in grave danger in the following period. The French government has already indicated that if it does not vaccinate itself, the player will not be able to attend the Roland Garrosson tournament scheduled for spring as well. (Reuters)